MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
the notes
$600,000K
Proceeds from exercise of
options and espp...
$6,158K
Net cash provided by
financing activities
$591,908K
Canceled cashflow
$14,250K
Increase (decrease) in
cash
$72,236K
Canceled cashflow
$519,672K
Issuance costs and
discounts associated with...
$13,528K
(payments) proceeds from
issuance of common...
-$722K
Maturities of marketable
securities
$192,759K
Sales of marketable
securities
$147,706K
Equity-based compensation
$16,324K
Other non-cash items,
net
-$8,800K
Depreciation and
amortization
$4,319K
Net cash used in
investing activities
-$410,743K
Net cash used in
operating activities
-$108,897K
Effect of exchange rate
changes on cash
-$32K
Canceled cashflow
$340,465K
Canceled cashflow
$29,443K
Purchases of marketable
securities
$746,089K
Net loss
-$122,931K
Investment in equity
securities
$4,615K
Purchase of property,
plant and equipment
$504K
Accounts payable and
accrued expenses
-$13,015K
Operating lease assets and
liabilities
-$1,521K
Deferred revenue
-$427K
Prepaid expenses and
other assets
$247K
Other liabilities,
net
-$199K
Back
Back
Cash Flow
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)
source: myfinsight.com